First-of-its-Kind vaccine targets rare liver cancer
NCT ID NCT06789198
Summary
This early-stage trial is testing a personalized vaccine for patients with fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer. The vaccine is designed to teach the patient's immune system to recognize and attack cancer cells that remain after initial treatments like surgery. Researchers will enroll about 20 patients to first check if the vaccine is safe and can trigger the desired immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Tuebingen
RECRUITINGTübingen, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsklinikum Tübingen, Kinderheilkunde I
NOT_YET_RECRUITINGTübingen, 72076, Germany
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.